Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

RVMD - Revolution Medicines, Inc.

IEX Last Trade
43.96
-0.110   -0.250%

Share volume: 29,116
Last Updated: Fri 27 Dec 2024 07:29:56 PM CET
Research and Development in Biotechnology (except Nanobiotechnology): 0.10%

PREVIOUS CLOSE
CHG
CHG%
$44.07
-0.11
-0.25%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
9%
Profitability 0%
Dept financing 4%
Liquidity 75%
Performance 4%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
1.05%
1 Month
-24.29%
3 Months
1.21%
6 Months
15.54%
1 Year
53.60%
2 Year
101.41%
Key data
Stock price
$43.96
P/E Ratio 
-13.71
DAY RANGE
$43.89 - $44.96
EPS 
-$3.58
52 WEEK RANGE
$27.17 - $62.40
52 WEEK CHANGE
$51.14
MARKET CAP 
7.121 B
YIELD 
N/A
SHARES OUTSTANDING 
167.039 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/04/2024
BETA 
1.52
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$1,381,757
AVERAGE 30 VOLUME 
$2,063,131
Company detail
CEO: Mark A. Goldsmith
Region: US
Website: revmed.com
Employees: 250
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

Revolution Medicines, Inc. focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trials for solid tumors, such as gynecologic and colorectal cancer tumors.

Recent news